Cargando…

Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report

BACKGROUND: Membrane-bound heat shock protein 70 (Hsp70) serves as a tumor-specific recognition structure for Hsp70-peptide (TKD) plus IL-2 activated NK cells. A phase I clinical trial has shown that repeated re-infusions of ex vivo TKD/IL-2-activated, autologous leukapheresis product is safe. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milani, Valeria, Stangl, Stefan, Issels, Rolf, Gehrmann, Mathias, Wagner, Beate, Hube, Kathrin, Mayr, Doris, Hiddemann, Wolfgang, Molls, Michael, Multhoff, Gabriele
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714296/ https://www.ncbi.nlm.nih.gov/pubmed/19549307 http://dx.doi.org/10.1186/1479-5876-7-50

Ejemplares similares

Role of membrane Hsp70 in radiation sensitivity of tumor cells
por: Murakami, Naoya, et al.
Publicado: (2015)

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
por: Shevtsov, Maxim, et al.
Publicado: (2016)

P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
por: Specht, HM, et al.
Publicado: (2014)

Irradiation-Induced Up-Regulation of HLA-E on Macrovascular Endothelial Cells Confers Protection against Killing by Activated Natural Killer Cells
por: Riederer, Isabelle, et al.
Publicado: (2010)

Hsp70 - a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck
por: Gehrmann, Mathias, et al.
Publicado: (2014)

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2022)

Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study
por: Kokowski, Konrad, et al.
Publicado: (2019)

Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
por: Gehrmann, Mathias, et al.
Publicado: (2012)

Potential Role of Hsp70 and Activated NK Cells for Prediction of Prognosis in Glioblastoma Patients
por: Lobinger, Dominik, et al.
Publicado: (2021)

Tumor Imaging and Targeting Potential of an Hsp70-Derived 14-Mer Peptide
por: Gehrmann, Mathias, et al.
Publicado: (2014)

Chronic Inflammation in Cancer Development
por: Multhoff, Gabriele, et al.
Publicado: (2012)

Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles
por: Gehrmann, Mathias K, et al.
Publicado: (2015)

Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer
por: Shevtsov, Maxim, et al.
Publicado: (2019)

Membrane Hsp70-supported cell-to-cell connections via tunneling nanotubes revealed by live-cell STED nanoscopy
por: Reindl, Judith, et al.
Publicado: (2019)

Radiosensitization of Normoxic and Hypoxic H1339 Lung Tumor Cells by Heat Shock Protein 90 Inhibition Is Independent of Hypoxia Inducible Factor-1α
por: Schilling, Daniela, et al.
Publicado: (2012)

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2021)

In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody
por: Stangl, Stefan, et al.
Publicado: (2011)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
por: Schnorfeil, Frauke, et al.
Publicado: (2014)

Plasmodium falciparum-Infected Erythrocytes Induce Granzyme B by NK Cells through Expression of Host-Hsp70
por: Böttger, Evelyn, et al.
Publicado: (2012)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

NK Cell-Based Immunotherapy in Renal Cell Carcinoma
por: Terrén, Iñigo, et al.
Publicado: (2020)

Editorial: NK Cell-Based Cancer Immunotherapy
por: Borrego, Francisco, et al.
Publicado: (2016)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
por: Chauhan, Sachin Kumar Singh, et al.
Publicado: (2020)

NK Cells as Potential Targets for Immunotherapy in Endometriosis
por: Ścieżyńska, Aneta, et al.
Publicado: (2019)

NK Cell-Based Immunotherapy for Hematological Malignancies
por: Sivori, Simona, et al.
Publicado: (2019)

Unleashing the power of NK cells in anticancer immunotherapy
por: Vogler, Meike, et al.
Publicado: (2021)

NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022)

Advances and challenges of immunotherapies in NK/T cell lymphomas
por: He, Ling, et al.
Publicado: (2023)

Editorial: NK cells in viral immunology and immunotherapy
por: Mulik, Sachin, et al.
Publicado: (2023)

Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
por: Shevtsov, Maxim, et al.
Publicado: (2016)

Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
por: Seliger, Barbara, et al.
Publicado: (2022)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h8uc7fehlft013ms81mfg8q5jf